Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-β in invasive carcinomas (Review)
The DOI matches its Crossref record.
Abstract
The proper structure of the extracellular matrix, in particular of the basement membrane and the adjacent interstitial matrix, are essential prerequisites for a proper function of tissues. Invasive growth in malignant tumors is associated with a destruction of various matrix structures. Due to extensive recent analyses significant advances have been made in the knowledge of the structure of the extracellular matrix, the composition of its most important constituents, their metabolism and that of matrix degrading enzymes. This information provides insight into the pathophysiology of malignant growth. Thereby, it has been shown that malignant tumor growth is associated with a loss of basement membrane (BM) material which, however, disappears not homogeneously, but affects various BM components to different degree. The loss of an intact BM as the first barrier is therefore the initial step of tumor invasion. Despite this loss there is evidence that the de novo synthesis of BM constituents in tumor and adjacent stromal cells is enhanced. Thus, it is obvious that BM material is degraded during the invasion process to significant degree. In addition, since there is a positive correlation between the amount of retained peritumoral BM and a higher degree of tumor cell differentiation the amount of retained BM material seems to represent a marker for the biological behaviour of the tumor cells. The loss of BM material is well explained by a significant expression of major matrix degrading enzymes, the matrix metalloproteinases (MMPs) both on the mRNA and protein level. Here again, there is considerable data indicating that both tumor and stroma cells are involved in the MMP synthesis. In addition to the loss of BM substances, the interstitial extracellular matrix (ECM) is disarranged. This disarrangement may comprise enhanced de novo synthesis ("desmoplasia") or dissolution by distinct MMPs (collagenases, such as MMP-1) reflecting obviously different reaction statuses of the stromal cells. Finally, significant work has been done on the elucidation of the role of regulating cytokine systems. To this regard, particular attention has been paid to the TGF-beta system and it has been shown that the major three isoforms of TGF-betas are upregulated both in tumor and stroma cells. Since the TGF-beta-effect is mainly mediated by a particular signalling system via the TGF-beta-receptors (TBRs), the investigation of this system has provided considerable insight into the role of TBRs which are now known to represent the most potent tumor suppressor genes. Thus frequent mutations in the TBR-II gene, one of the three TBRs, in various carcinomas suggest that these molecular alterations are responsible for both the loss of the control of cellular proliferation (in tumor cells) and altered matrix metabolism (in tumor and stroma cells). The further analysis of this major cytokine system therefore will provide us with major insights into the molecular abnormalities of invasive tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Padua, D., & Massagué, J. (2009) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 809
TGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523
Transforming growth factor‐β in stem cells and tissue homeostasis
Xu, X., Zheng, L., Yuan, Q., Zhen, G., Crane, J. L., Zhou, X., & Cao, X. (2018) · Bone Research · doi:10.1038/s41413-017-0005-4 · Cited by 414
Vascular Permeability and Drug Delivery in Cancers
Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 356
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
Geraldo, L. H. M., Spohr, T. C. L. D. S., Amaral, R. F. D., Fonseca, A. C. C. D., Garcia, C., Mendes, F. D. A., Freitas, C., dosSantos, M. F., & Lima, F. R. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00367-5 · Cited by 313
Cheng, N., Bhowmick, N. A., Chytil, A., Gorksa, A. E., Brown, K. A., Muraoka, R., Arteaga, C. L., Neilson, E. G., Hayward, S. W., & Moses, H. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208685 · Cited by 267
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
“TGF-b promotes the production and secretion of matrix metalloproteases MMP-2 and MMP-9, and it downregulates the expression of the protease inhibitor TIMP [3,66,116].”
BackgroundThe TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M., & Xu, R. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010005 · Cited by 174
“A major factor for this vascularization is vascular endothelial growth factor (VEGF), which is induced by TGF-β.”
BackgroundRamamonjisoa, N., & Ackerstaff, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00003 · Cited by 93
Metadata
- Authors
- Hagedorn, H., Bachmeier, B., & Nerlich, A.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2001-04-01
- Volume
- 18
- Issue
- 4
- Pages
- 669-81
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W1966177237
- Cited by
- 87
- References
- 0
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.